Abstract
Transforming growth factor (TGF)-β family members are multifunctional cytokines that elicit their effects on cells, including endothelial and mural cells, via specific type I and type II serine/threonine kinase receptors and intracellular Smad transcription factors. Knock-out mouse models for TGF-β family signaling pathway components have revealed their critical importance in proper yolk sac angiogenesis. Genetic studies in humans have linked mutations in these signaling components to specific cardiovascular syndromes such as hereditary hemorrhagic telangiectasia, primary pulmonary hypertension and Marfan syndrome. In this review, we present recent advances in our understanding of the role of TGF-β receptor signaling in vascular biology and disease, and discuss how this may be applied for therapy.
Similar content being viewed by others
Introduction
Transforming growth factor (TGF)-β is the prototypic member of a large family of evolutionarily conserved pleiotropic cytokines. Thirty three members are present in mammals, including three TGF-β isoforms, activins, and bone morphogenetic proteins (BMPs) 1, 2, 3. TGF-β family members have critical and specific roles during embryogenesis and in maintaining the homeostasis of adult tissues. Perturbations in their signaling pathways have been linked to a diverse set of developmental disorders and diseases, including cancer, fibrosis, auto-immune and cardiovascular diseases.
All TGF-β family ligands are generated as dimeric precursor proteins and subsequently cleaved by proteases and secreted 4. Members of the TGF-β family elicit their cellular effects by binding to a complex of type II and type I serine/threonine kinase transmembrane receptors (Figure 1). Five type II receptors and seven type I receptors, also termed activin receptor-like kinases (ALKs) are present in mammals 1, 2, 3. Within the ligand-induced heteromeric receptor complex, the constitutively active type II receptor phosphorylates the type I receptor on specific serine and threonine residues in the intracellular juxtamembrane region. TGF-β signals in most cells via TGF-β type II receptor (TβRII) and ALK5, activins via activin receptor type IIA (ActRIIA) and IIB and ALK4, and BMPs via BMP type II receptor (BMPRII), ActRIIs and ALK1, 2, 3 and 6. In endothelial cells (ECs) TGF-β can, in addition to ALK5, also signal via ALK1 5, 6. Upon type I receptor activation, receptor-regulated Smads (R-Smads) are recruited to, and phosphorylated by the type I receptor at the two serine residues in their extreme carboxyl termini. ALK4 and 5 (and 7) induce R-Smad2 and 3 phosphorylation, while ALK1, 2, 3 and 6 mediate phosphorylation of R-Smad1, 5 and 8. Activated R-Smads form complexes with the common mediator Smad4, and translocate into the nucleus, where they can regulate, together with other partner proteins, the transcription of specific target genes. Inhibitory (I)-Smads, i.e. Smad6 and -7, can inhibit the activation of R-Smads by competing with R-Smads for type I receptor interaction and by recruiting specific ubiquitin ligases or phosphatases to the activated receptor complex thereby targeting it for proteosomal degradation or dephosphorylation, respectively 1, 2, 3.
Access of ligands to the signaling type I and type II receptors is regulated by soluble ligand binding proteins and by accessory type III receptors. Examples of the latter class that have been most intensively studied are endoglin and betaglycan 4, 7. Both receptors are structurally related trans-membrane proteins with long extracellular and short intracellular domains and without an enzymatic motif. Compared with the type I and type II receptors, betaglycan is present in higher abundance and binds TGF-β1 and 3 with lower affinity 8. When TGF-β encounters a target cell expressing betaglycan, it is likely to interact first with betaglycan, which then presents it to TβRII. Betaglycan facilitates TGF-β signaling, in particular for TGF-β2 that binds with very weak affinity to TβRII alone 9, 10. Endoglin (CD105) is a homodimer that interacts with TGF-β1 and TGF-β3, but only when it is associated with TβRII 11, 12. Both the endoglin extracellular and intracellular domains interact with TβRII and ALK5 7. Endoglin is able to bind directly to BMPs 13, 14, 15.
In contrast to factors such as vascular endothelial growth factors (VEGFs) and angiopoietins that have prominent effects on EC behavior 16, TGF-β was initially discovered through its effects on fibroblasts 17 and subsequently shown to affect among other cell types, epithelial-, immune-, stem-, endothelial- and mural cells. This together with its highly cellular context dependent properties, frequently having opposite effects depending on the cellular differentiation state or the presence of other specific extracellular cues, has left the elucidation of the complex role of TGF-β family members in the cardiovascular system somewhat under-investigated. However, phenotypic and molecular characterizations of knock-out mice for TGF-β signaling components have demonstrated their critical role in angiogenesis, and importantly several cardiovascular syndromes were directly linked to mutations in their genes 4. TGF-β family members have now gained a prominent spot among other key cytokines that control vascular function. Our understanding of their complex role in cardiovascular biology and interplay with VEGF and other angiogenesis regulators is proceeding at a rapid pace. In this review we focus on recent insights into the function of TGF-β family members in the cardiovascular system and discuss how dysregulation of their signaling pathways contributes to vascular pathologies.
Vascular morphogenesis
Neovascularization, the formation of new functional microvascular networks, is a tightly controlled process regulated by several converging signaling pathways that are tightly coordinated in time and space. The formation of new blood vessels can occur via two processes, vasculogenesis and angiogenesis, both of which result in the formation of endothelial-lined tubes 16. During vasculogenesis new vessels arise de novo from a mass of proliferating cells, classically forming an inner core of hematopoietic precursor cells and an outer layer of ECs termed a blood island, followed by their subsequent migration, fusion and organization into a primary capillary plexus 18. Angiogenesis refers to the formation of new capillary networks by sprouting from pre-existing vessels 18, 19. Neovascularization is involved in growth and development, wound healing and several pathological situations such as tumor growth and metastasis, and cardiovascular disorders 20. While angiogenesis occurs during embryogenesis and in adult life, vasculogenesis was initially thought to occur only in the embryo, but some studies have suggested that circulating endothelial progenitor cells may also contribute to vessel formation in the adult 21. The formation of new capillaries involves EC activation, migration, alignment, proliferation, tube formation, branching and maturation of intercellular junctions and the surrounding basement membrane. All new blood vessels begin as simple EC-lined capillaries, but during vessel maturation, some vessels remain as capillaries covered by pericytes, and others develop into large vessels with support from a layer of smooth muscle cells (SMCs), forming a strong vessel wall.
Angiogenesis is a carefully balanced process, under the control of and fine tuned by a multitude of factors, including stimulators like VEGF and inhibitors such as thrombospondin 20. Considering the context-dependent effects of TGF-β in other cell systems, it is not surprising that its effect on blood vessel formation is biphasic 4. It can act as both a promoting and an inhibitory factor of angiogenesis for which the underlying mechanisms are starting to be uncovered.
Insights from knock-out mice
In vivo studies show that loss of TGF-β signaling components leads to abnormal formation of the primitive vascular plexus and decreased vessel wall integrity caused by irregular capillary vessel formation or impaired differentiation and recruitment of vascular SMCs. Targeted deletions of ALK1, ALK5, TβRII and endoglin in mice result in remarkably similar phenotypes (Figure 2). Embryos lacking any one of these components die during mid-gestation due to impaired vascular development, exhibiting hyper-dilated, leaky vessels 22, highlighting the importance of TGF-β signaling in the vascular system. The primary target cell for TGF-β is the EC since mice deficient in endothelial TβRII or ALK5 expression showed vascular defects in the yolk sac and embryonic lethality at embryonic day (E)10.5, which phenocopied mice lacking receptors in all cells 23. TGF-β not only affects the ECs, but is also important for proper differentiation and function of SMCs and pericytes. Mice lacking TβRII specifically in vascular SMCs also showed vascular defects in the yolk sac but at later stages of development, allowing the embryo to survive to E12.5 23.
At the intracellular level Smad1-, Smad2- or Smad4-deficient mice demonstrate a pre-angiogenesis lethality in embryos 22. In Smad1-deficient embryos this is accompanied with defects in chorion-allantoic circulation 24, 25. Smad5 knock-out and endothelial specific Smad4 knock-out have phenotypes reminiscent of TGF-β receptor knock-out mice 26, 27. Smad3-lacking mice are viable but die of impaired immunity and colon cancer 22.
The I-Smads, Smad6 and 7 were initially identified as EC shear stress response genes 28 and are highly expressed in specific regions of the heart 29, 30. Both I-Smads are strongly induced by TGF-β family members and participate in a negative feedback loop 1, 2, 3. Studies of mice deficient in Smad6 or Smad7 demonstrated their critical role in development and heart homeostasis 30, 31. Mice lacking Smad6 are born, but develop multiple heart abnormalities, including septation defects, ossification of the aorta, and have high blood pressure. While some of the Smad7-deficient mice die shortly after birth because of heart complications and abnormal heart rate, the majority die in utero due to cardiovascular defects, including outflow tract malformation and abnormality in ventricular septum and non-compaction.
Role of TGF-β signaling in ECs
TGF-β has been proposed to regulate the activation state of ECs by differentially activating two type I receptors, ALK5 and ALK1 5, 6. ALK5 is widely expressed in almost all tissues, but the expression of ALK1 is restricted to ECs and during embryogenesis at sites of angiogenesis 32.
TGF-β/ALK5 signaling induces Smad2/3 phosphorylation and blocks angiogenesis by inhibiting EC proliferation, tube formation and migration 6, 33. ALK5 induces the expression of fibronectin and plasminogen activator inhibitor type 1 (PAI-1), a negative regulator of EC migration 34. Interestingly, in mouse embryonic stem cell-derived ECs, the ALK5 kinase inhibitor SB-431542 enhances EC growth and integrity via up-regulation of the tight junction component Claudin-5, suggesting a role for ALK5 signaling in regulating vascular permeability 35. ALK5 indeed has been reported to increase TGF-β-induced EC permeability and actin cytoskeleton remodeling 36. By enhancing TβRII/ALK5 assembly clustered VE-cadherin promotes persistent and elevated TGF-β-induced Smad2/3 activation, indicating a positive role for VE-cadherin in TGF-β/ALK5-induced vessel stabilization 37. Taken together, TGF-β/ALK5 signaling plays an important role in keeping the endothelium quiescent.
In contrast to TGF-β/ALK5, TGF-β/ALK1 signaling induces Smad1/5 activation and has been shown to stimulate EC migration, proliferation and tube formation 33. Caveolin1 was shown to associate with ALK1 and to promote TGF-β/ALK1-induced responses 38. An important intracellular effector of ALK1 is Id1; its upregulation was shown to be required for TGF-β/ALK1-induced EC migration and tube formation 6. However, an inhibitory effect of ALK1 signaling on EC proliferation, migration and spouting has also been reported 39, 40. BMP9, identified as a ligand for the ALK1 and BMPR-II complex in ECs, was shown to inhibit EC migration and VEGF-induced angiogenesis 13, 14. These observations suggest that the effect of ALK1 signaling on angiogenesis is dependent on the context and specific ligand by which it is activated.
ALK1 and ALK5 signaling not only elicit opposite responses, but also physically interact with each other in ECs. ALK5-deficient ECs are not only defective in TGF-β/ALK5 signaling but also exhibit impaired TGF-β/ALK1 responses; ALK5 was found to be necessary for recruitment of ALK1 into a TGF-β receptor complex, and the kinase activity of ALK5 is essential for maximal ALK1 activation 33. Furthermore, ALK1 can directly antagonize ALK5/Smad2/3 signaling at the level of Smads 5, 6. The cross-talk between ALK1 and ALK5 signaling provides ECs with a TGF-β-dependent switch to fine tune EC function.
BMPs also play an important role in EC function. BMP6 promotes EC migration and tube formation via Smad1/5/8 phosphorylation 41. BMP4 was shown to induce proliferation and migration of ECs via stimulation of VEGF-A and Tie-2 signaling 42. In vivo BMPs were also found to induce tumor angiogenesis 43. BMP endothelial cell precursor-derived regulator (BMPER) interacts with BMP4, and regulates BMP4-mediated angiogenesis 44. Interestingly, inhibition of BMPRII using specific siRNA in human pulmonary arterial ECs was found to induce EC apoptosis via an increase in activated caspase-3 45. Upon exposure to hypoxia, BMPRII, phosphorylated Smad1/5/8 and Id1 expression were strongly reduced in these ECs, which may be of relevance to the pathogenesis of hypoxia-induced pulmonary hypertension 46. BMP9, which interacts with ALK1, is reported to be a circulating vascular quiescence factor 15.
Interestingly, there are ECs that express betaglycan and those that express endoglin. ECs expressing betaglycan respond to all three isoforms of TGF-β, whereas ECs that express endoglin (and not betaglycan) respond with high potency to TGF-β1 and -β3, but not -β2 47. In ECs that co-express betaglycan and endoglin, both proteins were shown to be part of a common TGF-β receptor complex 48. The co-receptor endoglin is predominantly expressed in highly proliferating vascular ECs, but is also reported to be detected on hematopoietic cells, syncytiotrophoblasts of term placenta, stromal cells and mesenchymal cells. Ectopic expression of endoglin inhibits TGF-β-induced growth inhibition in ECs, monocytes and myoblasts 12, 49 and extracellular matrix deposition 50. Endoglin regulates the fine-tuning between the ALK1 and ALK5 signaling pathways. It is required for TGF-β/ALK1 signaling and indirectly inhibits TGF-β/ALK5 signaling 49, 51. Suppression of endoglin gene expression using siRNA resulted in impaired TGF-β/ALK1 signaling responses 49. ECs derived from Eng−/− embryos were unable to proliferate in culture, displayed reduced migration, VEGF secretion and eNOS expression 49, 52. Interestingly, up-regulation of endoglin protects ECs from the apoptotic action of TGF-β1 53. Endoglin was recently shown to interact via its C-terminal PDZ binding motif with the scaffolding protein GIPC, which promotes endoglin cell surface retention 54. Elevated endoglin expression levels are used as a marker of tumor angiogenesis and endoglin antibodies coupled with toxin or radioactivity have been successfully used to target ECs in anti-angiogenic therapy 55, 56. Two endoglin splice forms have been reported, termed long (L) and short (S)-endoglin with pro- and anti-angiogenic activity, respectively 57. While the L-form is most abundantly expressed and promotes TGF-β/ALK1 signaling, S-endoglin expression was recently shown to be specifically high in senescent ECs and it preferentially promotes TGF-β/ALK5 signaling 58, 59. Transgenic mice overexpressing S-endoglin in ECs showed hypertension. Taken together, whereas L-endoglin contributes to the activation phase of angiogenesis and contributes to pathological neovascularization, S-endoglin is induced during EC senescence and may lead to age-associated pathologies such as hypertension 59.
Role of TGF-β signaling in vascular SMCs
Vascular SMCs express multiple type I and type II receptors for TGF-β family members 60. TGF-β is a potent stimulator of vascular SMC differentiation by activating the genetic program that includes a large set of SMC differentiation marker genes 61. Myocardin, an important coactivator of serum response factor, was shown to potently enhance TGF-β/Smad3-mediated activation of SM22α actin transcription 62. The zinc finger E-box binding transcription factor DeltaEF1 was also shown to have an important effector role in this respect by forming a complex with serum response factor and Smad3 63. TGF-β-induced growth inhibition of vascular SMCs was found to be ALK5- mediated via both Smad3-dependent and p38 MAP kinase-dependent signaling pathways 64. TGF-β was also shown to inhibit SMC migration in a non-Smad3-dependent pathway via up-regulation of cysteine rich protein 2 expression 65, 66. Interestingly, Smad3-deficient vascular SMCs demonstrated reduced growth inhibition by TGF-β, but did not show any attenuated TGF-β-mediated migratory response 64, 67.
Endoglin is also important for the formation of vascular SMCs. Ectopic endoglin expression in neural crest stem cells causes pericardial hemorrhage associated with altered vascular SMC investment in the walls of major vessels, suggesting a direct role of endoglin in myogenic differentiation 68.
Vascular SMC differentiation and function are also influenced by BMPs. The effect of BMPs depends on the source of SMCs studied as well as the local environment. While BMP2 stimulates vascular SMC migration, it prevents platelet-derived growth factor- induced vascular SMC proliferation via induction of the PPARγ/apoE axis 69, 70. BMP7 also inhibits the growth of vascular SMCs and helps maintain the vascular SMC phenotype in culture 71. In pulmonary SMCs both BMP7 and BMP4 induce apoptosis via a caspase 8- and 9-dependent mechanism 72. Interestingly, BMP4 induces micoRNA-21, leading to the repression of PDCD4, an inhibitor of smooth muscle cell gene expression; SMC differentiation is thereby stimulated 73.
Interaction between ECs and vascular SMCs
Tight regulation and close coordination between ECs and vascular SMCs are needed to form a mature vascular network. Vascular SMCs form abundant gap junctions with ECs and upon receiving signals from SMCs, ECs line up and recruit more SMCs 74.
TGF-β is an important regulator of the EC-SMC interaction. ECs produce latent TGF-β that upon EC-SMC interaction can be activated and induce SMC differentiation and function 75. Targeted deletions of several TGF-β signaling components have revealed the importance of TGF-β signaling in vSMC-EC contact. ALK-1- and Endoglin- deficient mice display defective remodeling of the primary capillary plexus of the yolk sac and aberrant development of SMCs 4, 5, 22, 76. Mice lacking TβRII, Smad5, Smad1 and TGF-β1 show defects in vasculature structure or blood vessel organization 22 indicative of a defect in EC lining and impaired SMC development.
TGF-β can also stimulate SMCs to produce VEGF partly in a p38 MAP kinase- 77, and a reactive oxygen species generation-dependent manner 78. The produced VEGF can influence both the ECs as well as SMCs, by inducing their growth and differentiation. Interestingly, VEGF was found to inhibit TGF-β release by ECs 79.
Besides influencing their growth, TGF-β and BMP are also potent SMC differentiation factors and crucial regulators to switch SMCs from an undifferentiated phenotype to a contractile phenotype 61. Furthermore, TGF-β can also induce trans-differentiation of ECs (Endo-MT) into smooth muscle-like cells. TGF-β induces the expression of α-smooth muscle actin and smooth muscle myosin in ECs in a Snail-dependent manner 80 and blocking TGF-β signaling with neutralizing antibodies abrogates the induction of smooth muscle markers in ECs 75.
Vascular disorders and TGF-β signaling
In recent years multiple cardiovascular disorders have been linked to alterations in TGF-β/BMP signaling pathways, several of which will be discussed below. Increased understanding of the molecular mechanisms has been achieved by studying mouse models that mimic these human diseases. Importantly, these mouse models also allow for testing of therapeutic strategies that aim to normalize the perturbed signaling balance.
Hereditary hemorrhagic telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT), or Osler-Rendu-Weber syndrome, is an autosomal dominant vascular dysplasia, characterized by the development of mucocutaneous telangiectasias and arteriovenous malformations in the brain, lungs, liver, and gastrointestinal tract (Figure 3). There is variability in the organs affected, even between individuals within families 81. Three genes are causally related to HHT, i.e. endoglin mutated in HHT type 1 (HHT-1) 82; ALK1 mutated in HHT-2 83 and mutation in Smad4 causing a syndrome consisting of both juvenile polyposis and an HHT phenotype 84. In vivo, EC-specific deletion of ALK1 caused vascular malformations mimicking all pathologic features of HHT-2 vascular lesions 85, while endoglin heterozygous mice have dilated and fragile blood vessels which resemble clinical manifestations of HHT-1 patients 76, 86.
While circulating levels of TGF-β were reduced in HHT-1 patients compared to control, this was not found in HHT-2 patients, suggesting that reduced endoglin levels on HHT-1 ECs might lead to reduced TGF-β-1 secretion 7. Since TGF-β is important for SMC differentiation, and recruitment of SMCs to new vessels as well as their growth require TGF-β, this reduced TGF-β secretion might explain the formation of fragile and leaky vessels in HHT-1 patients. Multiple clinical trials in HHT patients are ongoing with anti-angiogenesis agents, including bevacizumab, a neutralizing antibody against VEGF, thalidomide and interferon α-2b to inhibit bleedings and other vascular malformations associated with HHT (http://www.hht.org/).
Marfan syndrome and Loeys-Dietz syndrome (MFS and LDS)
Marfan syndrome (MFS) is a genetic connective tissue disorder caused by mutations in the fibrillin gene 87. Typical MFS can affect the skeletal system, ocular system, cardiovascular system, pulmonary system as well as other organs, with defects in aorta and heart valves giving the most severe complications. Fibrillin contains several motifs homologous to latent TGF-β binding protein (LTBP), and has been shown to interact with LTBP and control TGF-β bioavailability 4. TGF-β is bound and kept inactive by the LTBP-fibrillin complex. In fibrillin-1-deficent mice, a model of MFS, fibrillin-1 deficiency was found to diminish the sequestration of latent TGF-β to the extracellular matrix, thereby leading to increased TGF-β activation 88. Marfan syndrome type 2 is caused by mutation in the TβRII gene locus. Three prominent features of Marfan's syndrome in humans, i.e. dilatation of the aortic root, air-space widening and skeletal myopathy, can be prevented and even reversed in the mouse model by treatment with losartan, which blocks the angiotensin II type 1 receptor and antagonizes TGF-β signaling 89, 90.
The Loeys-Dietz syndrome is a recently described autosomal dominant aortic-aneurysm syndrome presenting with cardiovascular and skeletal manifestations consistent with those seen in MFS, along with other features not present in MFS. Typical Loeys-Dietz syndrome is characterized by a mutation in either TβRI or TβRII 91. The molecular mechanism of Loeys-Dietz syndrome is complex and poorly understood; although mutations in TβR are inactivating its function, they lead paradoxically to overactive TGF-β signaling, as measured by accumulation of phosphorylated Smad2 in the nucleus and expression levels of connective-tissue growth factor 92. Thus TGF-β antagonists may also alleviate manifestations of Loeys-Dietz syndrome. In a recent clinical study with 18 MFS patients, losartan decreased the rate of progressive aortic-root dilation 93 (http://www.marfan.org/nmf/index.jsp).
Pre-eclampsia
Pre-eclampsia, which involves a raise in blood pressure, is a major cause of maternal, fetal, and neonatal mortality. The clinical manifestations of pre-eclampsia reflect widespread EC dysfunction, resulting in vasoconstriction, endo-organ ischemia and increased vascular permeability 94. Soluble endoglin (solEng), a placenta-derived 65 kD soluble form of endoglin and soluble fms-like tyrosine kinase 1 (sFlt1, an inhibitor of VEGF) are both considered to be clinical indicators for pre-eclampsia 95. Just before the onset of pre-eclampsia circulating levels of solEng are found to be markedly elevated and it cooperates with sFlt in the pathogenesis of pre-eclampsia in rats 96. SolEng was found to inhibit TGF-β-mediated activation of eNOS, thereby affecting vascular tone. SolEng disrupts EC function, inhibiting EC tube formation and enhancing capillary permeability. SolEng is formed by proteolytic cleavage, but the protease involved remains to be identified. Upon identification of this protease involved in endoglin shedding, it will be interesting to explore whether its targeting could be beneficial for treatment of pre-eclampsia. Circulating solEng levels may be a useful diagnostic marker in pre-eclampsia 4.
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a disease caused by constriction of small pulmonary arteries leading to an increase in blood pressure (Figure 4). Aberrant proliferation and dysfunction of ECs and SMCs contribute to vascular remodeling 97, 98. Heterozygous germ line mutations in the BMP receptor II gene (BMPRII) have been found in more than 80% of familial PAH patients. In addition, about 20% of patients with idiopathic PAH were reported to have mutations in BMPRII 99, 100. A recent study has implicated mutations of ALK1 in children with PAH 101. Over-expression of a mutant form of BMPRII in SMCs of transgenic mice causes an increase in pulmonary arterial pressure and pulmonary arterial muscularization, resembling some manifestations of PAH patients 102. Mutations in BMPRII also can deregulate Id gene expression 103. BMPRII signaling was found to be essential for BMP-mediated regulation of vascular SMC growth and differentiation 104. Clinical trials with prostanoids, endothelin antagonists and phosphodiesterase inhibitors have shown promising results in the treatment of PAH. It will be interesting to examine the interplay between the targets of these therapeutics and deregulated BMPRII signaling in PAH 105.
Cardiac remodeling and hypertrophy
Cardiac remodeling describes the alteration in size, shape and function of the left ventricle in response to changes in hemodynamic loading conditions, neurohormonal activation, or induction of local mediators that alter the structural characteristics of the myocardium. TGF-β is a crucial regulator of cardiac remodeling through its direct and potent actions in mediating cardiomyocyte growth, fibroblast activation and extracellular matrix deposition 106.
TGF-β levels are markedly induced in the hypertrophic myocardium. Angiotensin II via the angiotensin type 1 receptor promotes cardiomyocyte growth and stimulates fibroblast proliferation and expression of extracellular matrix components 107, 108. Angiotensin, a potent vasoconstrictor, stimulates TGF-β1 mRNA and protein expression and may through its induction of thrombospondin lead to TGF-β activation 109, indicating that TGF-β1 acts downstream of angiotensin signaling 107. In addition, angiotensin has been shown to directly lead to Smad3 activation via a mechanism that is not well understood 110. The renin-angiotensin system (RAS) plays an important role in cardiac remodeling and clinical trials have documented the beneficial effects of angiotensin II inhibition in patients with myocardial infarction and heart failure 111. Indeed, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy 112. Furthermore it has been reported that TGF-β stimulation alters the program of differentiation-related gene expression in isolated cardiac myocytes, promoting the synthesis of fetal contractile proteins, characteristic of pressure-overload hypertrophy 113. Over-expression of TGF-β in transgenic mice results in cardiac hypertrophy which is characterized by both interstitial fibrosis and hypertrophic growth of cardiac myocytes 114. The local production of TGF-β in hypertrophic myocardium and the link between the RAS system and TGF-β strongly implicate the role of TGF-β in hypertrophic response. All these results demonstrate the importance of TGF-β in mediating hypertrophic cardiac remodeling, however, limited knowledge is available on the signaling pathways responsible for TGF-β action in hypertrophy.
Concluding remarks
The pivotal importance of TGF-β family members in angiogenesis is underscored by the observations that nearly all knock-out mice for specific TGF-β family signaling components die during midgestation due to a yolk sac angiogenesis defect and that mutations in the genes encoding TGF-β pathway components are linked to an increasing number of human pathologies with vascular dysfunction. In concordance with these findings in vitro studies with different TGF-β family members have revealed potent effects on the function of ECs and vascular SMCs, affecting e.g., proliferation, differentiation, migration and extracellular matrix production. However, results obtained by different laboratories are sometimes in apparent conflict, but this can largely be attributed to context-dependent functions of TGF-β family members. Ligand concentration, cell density, cell type, media and matrix coating may determine specific cellular responses to TGF-β family members. TGF-β also plays an important role in the interplay between ECs and vascular SMCs. Recent data indicate that TGF-β is capable of mediating EndoMT, a transdifferentiation of ECs into SMC-like cells 115.
With misregulation of TGF-β signaling at the heart of cardiovascular disorders, the cognate signaling components represent interesting targets for therapy. The first large-scale clinical trials with losartan to treat MFS are underway and results are eagerly awaited. Results from one vascular disorder may open opportunities for development of therapies in other vascular pathologies. Whereas high levels of circulating solEng may lead to pre-eclampsia by causing an EC dysfunction in multiple organs, solEng may be explored for anti-angiogenic activity in curbing tumor angiogenesis.
References
Heldin C-H, Miyazono K, ten Dijke P . TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465–471.
Shi Y, Massagué J . Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113:685–700.
Schmierer B, Hill CS . TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007; 8:970–982.
ten Dijke P, Arthur HM . Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8:857–869.
Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000; 97:2626–2631.
Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P . Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 2002; 21:1743–1753.
ten Dijke P, Goumans MJ, Pardali E . Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008; 11:79–89.
López-Casillas F, Wrana JL, Massagué J . Betaglycan presents ligand to the TGFβ signaling receptor. Cell 1993; 73:1435–1444.
Del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY . In the absence of type III receptor, the transforming growth factor (TGF)-β type II-B receptor requires the type I receptor to bind TGF-β2. J Biol Chem 2004; 279:22765–2272.
Sankar S, Mahooti-Brooks N, Centrella M, McCarthy TL, Madri JA . Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor β2. J Biol Chem 1995; 270:13567–13572.
Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267:19027–19030.
Lastres P, Letamendía A, Zhang H, et al. Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996; 133:1109–1121.
Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007; 120:964–972.
David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S . Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007; 109:1953–1961.
David L, Mallet C, Keramidas M, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 2008; 102:914–922.
Adams RH, Alitalo K . Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8:464–478.
Roberts AB, Anzano MA, Meyers CA, et al. Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry 1983; 22:5692–5698.
Risau W . Mechanisms of angiogenesis. Nature 1997; 386:671–674.
Folkman J, D'Amore PA . Blood vessel formation: what is its molecular basis? Cell 1996; 87:1153–1155.
Carmeliet P . Angiogenesis in life, disease and medicine. Nature 2005; 438:932–936.
Eguchi M, Masuda H, Asahara T . Endothelial progenitor cells for postnatal vasculogenesis. Clin Exp Nephrol 2007; 11:18–25.
Goumans MJ, Mummery C . Functional analysis of the TGFβ receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 2000; 44:253–265.
Carvalho RL, Itoh F, Goumans MJ, et al. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFβ receptors in mice. J Cell Sci 2007; 120:4269–4277.
Lechleider RJ, Ryan JL, Garrett L, et al. Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol 2001; 240:157–167.
Tremblay KD, Dunn NR, Robertson EJ . Mouse embryos lacking Smad1 signals display defects in extra-embryonic tissues and germ cell formation. Development 2001; 128:3609–3621.
Lan Y, Liu B, Yao H, et al. Essential role of endothelial Smad4 in vascular remodeling and integrity. Mol Cell Biol 2007; 27:7683–7692.
Chang H, Zwijsen A, Vogel H, Huylebroeck D, Matzuk MM . Smad5 is essential for left-right asymmetry in mice. Dev Biol 2000; 219:71–78.
Topper JN, Cai J, Qiu Y, et al. Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci USA 1997; 94:9314–9319.
Zwijsen A, Goumans MJ, Lawson KA, Van Rooijen MA, Mummery CL . Ectopic expression of the transforming growth factor beta type II receptor disrupts mesoderm organisation during mouse gastrulation. Dev Dyn 1999; 214:141–151.
Galvin KM, Donovan MJ, Lynch CA, et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000; 24:171–174.
Chen Q, Chen H, Zheng D, et al. Smad7 is required for the development and function of heart. J Biol Chem 2008 Oct 24. doi:10.1074/jbc.M807233200.
Roelen BA, van Rooijen MA, Mummery CL . Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn 1997; 4:418–430.
Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell 2003; 12:817–828.
Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ . Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996; 134:1563–1571.
Watabe T, Nishihara A, Mishima K, et al. TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 2003; 163:1303–1311.
Birukova AA, Adyshev D, Gorshkov B, Birukov KG, Verin AD . ALK5 and Smad4 are involved in TGF-β1-induced pulmonary endothelial permeability. FEBS Lett 2005; 579:4031–4037.
Rudini N, Felici A, Giampietro C, et al.VE-cadherin is a critical endothelial regulator of TGF-β signalling. EMBO J 2008; 27:993–1004.
Santibanez JF, Blanco FJ, Garrido-Martin EM, Sanz-Rodriguez F, del Pozo MA, Bernabeu C . Caveolin-1 interacts and cooperates with the transforming growth factor-β type I receptor ALK1 in endothelial caveolae. Cardiovasc Res 2008; 77:791–799.
Lamouille S, Mallet C, Feige JJ, Bailly S . Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002; 100:4495–4501.
Mallet C, Vittet D, Feige JJ, Bailly S . TGFβ1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells 2006; 24:2420–2427.
Valdimarsdottir G, Goumans MJ, Rosendahl A, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002; 106:2263–2270.
Suzuki Y, Montagne K, Nishihara A, Watabe T, Miyazono K . BMPs promote proliferation and migration of endothelial cells via stimulation of VEGF-A/VEGFR2 and angiopoietin-1/Tie2 signalling. J Biochem 2008; 143:199–206.
Langenfeld EM, Langenfeld J . Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004; 2:141–149.
Heinke J, Wehofsits L, Zhou Q, et al. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res 2008; 103:804–812.
Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 2006; 98:209–217.
Takahashi K, Kogaki S, Matsushita T, Nasuno S, Kurotobi S, Ozono K . Hypoxia induces alteration of bone morphogenetic protein receptor signaling in pulmonary artery endothelial cell. Pediatr Res 2007; 61:392–397.
Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massagué J . Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 1990; 265:20533–20538.
Wong SH, Hamel L, Chevalier S, Philip A . Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-β signalling receptors. Eur J Biochem 2000; 267:5550–5560.
Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 2004; 23:4018–4028.
Obreo J, Díez-Marques L, Lamas S, et al. Endoglin expression regulates basal and TGF-β1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem 2004; 14:301–310.
Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C . Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-β receptor complex. J Cell Physiol 2005; 204:574–584.
Jerkic M, Rodríguez-Barbero A, Prieto M, et al. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 2006; 69:845–854.
Li C, Issa R, Kumar P, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003; 116:2677–2685.
Lee NY, Ray BN, How T, Blobe GC . Endoglin promotes transforming growth factor-β-mediated smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 2008; 283: 32527–32533.
Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M . Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003; 22:6557–6563.
Duff SE, Li C, Garland JM, Kumar S . CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17:984–992.
Pérez-Gómez E, Eleno N, López-Novoa JM, et al. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 2005; 24:4450–4461.
Velasco S, Alvarez-Muñoz P, Pericacho M, et al. L- and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 2008; 121:913–919.
Blanco FJ, Grande MT, Langa C, et al. S-Endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 2008; 103:1383–1392.
Bobik A . Transforming growth factor-βs and vascular disorders. Arterioscler Thromb Vasc Biol 2006; 26:1712–1720.
Owens GK . Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75:487–517.
Qiu P, Ritchie RP, Fu Z, et al. Myocardin enhances Smad3-mediated transforming growth factor-β1 signaling in a CArG box-independent manner: Smad-binding element is an important cis element for SM22a transcription in vivo. Circ Res 2005; 97:983–991.
Nishimura G, Manabe I, Tsushima K, et al. DeltaEF1 mediates TGF-β signaling in vascular smooth muscle cell differentiation. Dev Cell 2006; 11:93–104.
Feinberg MW, Watanabe M, Lebedeva MA, et al. Transforming growth factor-β1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem 2004; 279:16388–16393.
Wei J, Gorman TE, Liu X, et al. Increased neointima formation in cysteine-rich protein 2-deficient mice in response to vascular injury. Circ Res 2005; 97:1323–1331.
Lin DW, Chang IC, Tseng A, et al. Transforming growth factor β up-regulates cysteine-rich protein 2 in vascular smooth muscle cells via activating transcription factor 2. J Biol Chem 2008; 283:15003–15014.
Kobayashi K, Yokote K, Fujimoto M, et al. Targeted disruption of TGF-β-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ Res 2005; 96:904–912.
Mancini ML, Verdi JM, Conley BA, et al. Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev Biol 2007; 308: 520–533.
Willette RN, Gu JL, Lysko PG, Anderson KM, Minehart H, Yue T . BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res 1999; 36:120–125.
Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118:1846–1857.
Dorai H, Vukicevic S, Sampath TK . Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000; 184:37–45.
Lagna G, Nguyen PH, Ni W, Hata A . BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006; 291:L1059–1067
Davis BN, Hilyard AC, Lagna G, Hata A . SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454:56–61.
Hungerford JE, Owens GK, Argraves WS, Little CD . Development of the aortic vessel wall as defined by vascular smooth muscle and extracellular matrix markers. Dev Biol 1996; 178:375–392.
Ding R, Darland DC, Parmacek MS, D'Amore PA . Endothelial-mesenchymal interactions in vitro reveal molecular mechanisms of smooth muscle/pericyte differentiation. Stem Cells Dev 2004; 13:509–520.
Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000; 217: 42–53.
Yamamoto T, Kozawa O, Tanabe K, et al. Involvement of p38 MAP kinase in TGF-β-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem 2001; 82:591–598.
Black SM, Grobe A, Mata-Greenwood E, Noskina Y . Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-β1 and reactive oxygen species: a requirement for NAD(P)H oxidase. Conf Proc IEEE Eng Med Biol Soc 2004; 7:5053–5056.
Dongmei L, Cuili Z, Song F, Lubenec I, Tian Y, Song QH . VEGF regulates FGF-2 and TGF-β1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc Res 2008 Oct 2. doi: 10.1016/j.mvr.2008.09.007.
Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K . Snail is required for TGFβ-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 2008; 121:3317–3324.
Abdalla SA, Letarte M . Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43:97–110.
McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8:345–351.
Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13:189–195.
Gallione CJ, Richards JA, Letteboer TG, et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006; 43:793–797.
Park SO, Lee YJ, Seki T, et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008; 111:633–642.
Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M . Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 2001; 158:2011–2020.
Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 2006; 43:769–787.
Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33:407–411.
Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13:204–210.
Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117–121.
Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med 2006; 355:788–798.
Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2003; 37:275–281.
Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC . Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358:2787–2795.
Sibai BM . Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 2006; 30:16–19.
Levine RJ, Lam C, Qian C, et al. CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992–1005.
Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642–649.
Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105:1672–1678.
Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155:411–419.
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26:81–84.
Machado RD, Aldred MA, James V, et al. Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27:121–132.
Fujiwara M, Yagi H, Matsuoka R, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008; 72:127–133.
West J, Fagan K, Steudel W, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004; 94:1109–1114.
Yang J, Davies RJ, Southwood M, et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res 2008; 102:1212–1221.
Yu PB, Deng DY, Beppu H, et al. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem 2008; 283:3877–3888.
Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV . Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917–1928.
Bujak M, Ren G, Kweon HJ, et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007; 116:2127–2138.
Rosenkranz S . TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63:423–432.
Sadoshima J, Xu Y, Slayter HS, Izumo S . Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977–984.
Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE . Thrombospondin 1 mediates angiotensin II induction of TGF-β activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 2006; 339:633–641.
Wang W, Huang XR, Canlas E, et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006; 98:1032–1039.
Pfeffer JM, Fischer TA, Pfeffer MA . Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol 1995; 57:805–826.
Devereux RB, Lyle PA . Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study. Expert Opin Pharmacother 2004; 5:2311–2320.
Parker TG, Packer SE, Schneider MD . Peptide growth factors can provoke “fetal” contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990; 85:507–514.
Rosenkranz S, Flesch M, Amann K, et al. Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 2002; 283:H1253–1262.
Goumans MJ, Zonneveld AJ, ten Dijke P . TGFβ-induced endothelial to mesenchymal transition; a switch to cardiac fibrosis? Trends Cardiovasc Med, in press.
Larsson J, Goumans MJ, Sjöstrand LJ, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 2001; 20:1663–1673.
Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918–924.
Acknowledgements
We thank colleagues for valuable discussion. Our studies on the role of TGF-β in angiogenesis are supported by the Centre for Biomedical Genetics, Ludwig Institute for Cancer Research, the Dutch Cancer Society (UL-2005-3371) and EU FP6 grants Angiotargeting and Tumor-Host-Genomics.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goumans, MJ., Liu, Z. & ten Dijke, P. TGF-β signaling in vascular biology and dysfunction. Cell Res 19, 116–127 (2009). https://doi.org/10.1038/cr.2008.326
Published:
Issue Date:
DOI: https://doi.org/10.1038/cr.2008.326
Keywords
This article is cited by
-
Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications
Drugs in R&D (2024)
-
Molecular Insights into the Relationship Between Platelet Activation and Endothelial Dysfunction: Molecular Approaches and Clinical Practice
Molecular Biotechnology (2024)
-
The role of TGF-beta3 in cartilage development and osteoarthritis
Bone Research (2023)
-
Conserved miR-370-3p/BMP-7 axis regulates the phenotypic change of human vascular smooth muscle cells
Scientific Reports (2023)
-
Association Study of Transforming Growth Factor Beta 1 + 29 T/C exon 1 Polymorphism in Breast Cancer Patients from North Indian Population
Applied Biochemistry and Biotechnology (2023)